PharmaCielo Ltd.

TSXV:PCLO Stock Report

Market Cap: CA$15.3m

PharmaCielo Management

Management criteria checks 2/4

PharmaCielo's CEO is Marc Lustig, appointed in Jul 2023, has a tenure of 1.5 years. directly owns 3.86% of the company’s shares, worth CA$589.92K. The average tenure of the management team and the board of directors is 2.5 years and 5.8 years respectively.

Key information

Marc Lustig

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure1.5yrs
CEO ownership3.9%
Management average tenure2.5yrs
Board average tenure5.8yrs

Recent management updates

Recent updates

Is PharmaCielo (CVE:PCLO) Using Too Much Debt?

Oct 04
Is PharmaCielo (CVE:PCLO) Using Too Much Debt?

Is PharmaCielo (CVE:PCLO) Using Too Much Debt?

Feb 25
Is PharmaCielo (CVE:PCLO) Using Too Much Debt?

PharmaCielo (CVE:PCLO) Is Making Moderate Use Of Debt

Aug 03
PharmaCielo (CVE:PCLO) Is Making Moderate Use Of Debt

Is PharmaCielo (CVE:PCLO) Weighed On By Its Debt Load?

Dec 23
Is PharmaCielo (CVE:PCLO) Weighed On By Its Debt Load?

Is PharmaCielo (CVE:PCLO) A Risky Investment?

May 14
Is PharmaCielo (CVE:PCLO) A Risky Investment?

Should PharmaCielo (CVE:PCLO) Be Disappointed With Their 9.8% Profit?

Feb 16
Should PharmaCielo (CVE:PCLO) Be Disappointed With Their 9.8% Profit?

CEO

Marc Lustig (50 yo)

1.5yrs

Tenure

CA$57,500

Compensation

Mr. Marc Lustig, M. Sc., M. B.A., had been an Executive Chairman at IM Cannabis Corp. since December 29, 2020 and had been its Director since October 11, 2019 until June 05, 2024. He has been Chairman and...

Leadership Team

NamePositionTenureCompensationOwnership
Marc Lustig
Chairman & CEO1.5yrsCA$57.50k3.86%
CA$ 589.9k
Ian Atacan
CFO, Corporate Secretary & Director3.6yrsCA$275.00k0.36%
CA$ 55.4k
Andres Botero
Chief Operating Officerno dataCA$290.57kno data
Decio de Castro Filho
Chief Medical Officer2.5yrsno datano data

2.5yrs

Average Tenure

Experienced Management: PCLO's management team is considered experienced (2.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Marc Lustig
Chairman & CEO4.2yrsCA$57.50k3.86%
CA$ 589.9k
Ian Atacan
CFO, Corporate Secretary & Director2.5yrsCA$275.00k0.36%
CA$ 55.4k
Anders Milton
Member of Medical & Scientific Advisory Board8.2yrsno datano data
Douglas Bache
Independent Director6yrsCA$60.00k0.041%
CA$ 6.3k
Riccardo Polosa
Member of Medical & Scientific Advisory Board5.8yrsno datano data
Nadia Crosignani
Member of Medical & Scientific Advisory Board5.8yrsno datano data
Konstantinos Farsalinos
Member of Medical & Scientific Advisory Board5.8yrsno datano data
Gerard Madlambayan
Member of Medical & Scientific Advisory Board5.8yrsno datano data
Solomon Rataemane
Member of Medical & Scientific Advisory Board5.8yrsno datano data
David Richardson
Member of Medical & Scientific Advisory Board5.8yrsno datano data
William Petron
Lead Independent Director3.6yrsCA$541.68k2.6%
CA$ 397.1k

5.8yrs

Average Tenure

Experienced Board: PCLO's board of directors are considered experienced (5.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/08 22:38
End of Day Share Price 2025/01/08 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

PharmaCielo Ltd. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullStifel Canada
Robert FaganStifel Canada